Frevecitinib
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Frevecitinib
- Molecular weight
- 415.46
- Structure (SMILES)
- Cn1c(=O)n([C@H]2CCCN(C(=O)CC#N)C2)c2nc(-c3cnn4ccccc34)ccc21
- frevecitinib
- Frevecitinib
- frevecitinib [INN]
- FREVECITINIB [USAN]
- frevecitinib inn
- frevecitinib usan
- kn 002
- KN-002
- kn002
- KN002
- CAS registry numbers
- 1299417-07-4
- ChEMBL ID
- CHEMBL6068013
- InChIKey
- ASOKEXGIQLZRHH-HNNXBMFYSA-N
- PubChem compound IDs
- 67123870
- FDA ingredient codes (UNII)
- 5N5L287M8T
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- frevecitinib
- Type
- Synthetic organic
- Drug name stem
- -tinib
- Condition
- Pulmonary Disease, Chronic Obstructive
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000341
- Subject identifier
- D029424
- Condition
- Asthma
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0004979
- Subject identifier
- D001249
- Condition
- Inflammation
- Highest recorded phase
- 2
- Condition identifier
- MP:0001845
- Subject identifier
- D007249
- Condition identifier
- EFO_0000341
- Condition identifier
- MONDO_0004979
- Condition identifier
- MONDO_0004979
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005002
- Highest recorded phase
- 1
- Condition identifier
- MP_0001845
- Hydrogen bond acceptors
- 8
- Hydrogen bond donors
- 0
- Polar surface area
- 101.22
- Calculated partition coefficient (ALogP)
- 2.13
- Calculated partition coefficient (XLogP)
- 0.9
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 3
- Heavy atoms
- 31
- Molecular formula
- C22H21N7O2
- Monoisotopic mass
- 415.17567294
- Natural product
- No
Related records
Trials (2)
- A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma
- Single and Multiple Ascending Dose Study of KN-002
In development for (2)
- Asthma Phase 1
- Chronic obstructive pulmonary disease Phase 1